Lunit's AI Now Powers Cancer Screening for Over 14% of Italy's Population Through Public Health System

USA - English

• Italia - Italiano

With deployments in Lazio, Lombardia, and Veneto regions, Lunit strengthens its foothold in one of Europe's largest public healthcare systems

SEOUL, South Korea, Aug. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a significant expansion of its footprint in Italy's public healthcare system. As of June 2025, more than 10 Local Health Authorities—commonly known as ASL (Azienda Sanitaria Locale)—are using Lunit's AI solutions to enhance cancer screening and optimize imaging workflow. These ASLs collectively serve a population of over 8.5 million, accounting for approximately 14% of Italy's total population.

The deployments span multiple regions, including Lazio, Lombardia, and Veneto—three of the country's most populous and high-demand areas. Lunit's AI solutions—Lunit INSIGHT MMG for mammography and Lunit INSIGHT CXR for chest X-ray—are currently in use to support radiologists in detecting breast and lung abnormalities with greater speed and accuracy.

Italy represents one of the key European markets where AI is being adopted at scale in public healthcare, demonstrating how population-wide deployment can be achieved. The growing adoption of Lunit's AI solutions within this system marks a critical milestone in the real-world application of AI at scale.

"Achieving meaningful scale in a nationalized healthcare environment is no easy feat," said Brandon Suh, CEO of Lunit. "Our work in Italy demonstrates how AI can be successfully integrated into public screening programs and impact care across an entire country—not just in isolated pilot settings."

Lunit's AI is currently being used across major regions including Lazio (Rome), Lombardia (Milan), and Veneto (Venice), with select ASLs such as ASL Roma 2 and ULSS2 Marca Trevigiana having implemented the solution in workflows. These deployments were carried out in collaboration with global medical device companies, who supported seamless integration into existing imaging infrastructure.

The momentum is set to continue. Lunit expects to secure additional agreements with ASLs covering nearly 4 million more residents by December 2025. Upon completion, its AI will help support diagnostics for roughly 20% of the entire Italian population—a scale rarely achieved by any medical AI provider in Europe.

This progress reinforces Lunit's broader European strategy, where the company is playing a leading role in advancing AI adoption across public health systems. By embedding AI into population-wide screening initiatives, Lunit aims to bridge the gap between technological innovation and equitable access to early cancer detection.

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

SOURCE Lunit